Comparative Pharmacology
Head-to-head clinical analysis: CAMBIA versus SOLARAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMBIA versus SOLARAZE.
CAMBIA vs SOLARAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating inflammation, pain, and fever.
Solaraze (diclofenac sodium) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation and pain. In actinic keratosis, it may also induce apoptosis and decrease keratinocyte proliferation.
50 mg orally once daily as needed for acute migraine, maximum 1 packet (50 mg) per 24 hours.
Apply 0.5 mL (1 unit dose) topically to actinic keratoses twice daily for 2 to 4 weeks, then 1 week off, repeat for a total of 3 treatment cycles.
None Documented
None Documented
Terminal elimination half-life of diclofenac (active moiety) is approximately 1.9-2.1 hours. The clinical context: short half-life supports twice-daily dosing for acute pain.
Following topical application, the terminal elimination half-life of diclofenac from plasma is approximately 12 hours (range 8-15 hours). This reflects the slow absorption and distribution from the skin depot, with clinical relevance for twice-daily dosing.
Approximately 50% of a dose is excreted in urine primarily as metabolites and conjugates, with less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 40%.
Solaraze (diclofenac sodium 3% gel) is primarily eliminated via hepatic metabolism followed by renal excretion of metabolites. Approximately 65% of a dose is excreted in urine as conjugated metabolites, with less than 1% as unchanged drug. About 35% is eliminated in feces via biliary excretion of metabolites.
Category C
Category C
NSAID
NSAID